Xiamen Jiqing Biomedical Technology Co., Ltd. focus on IVD products, include R&D, production and sales. The founder in charge of the company has more than 20 years of experience in R&D and production of IVD products. In 2016, as a talents in Xiamen, he led the team through years of hard work to form a production system that can meet the GMP requirements of MDD with a daily capacity of 300000-500000 tests, including supporting facilities. Our company has passed ISO 13485 system certification for D level production and clean workshop, C level inspection and purification workshop, supporting packaging workshop and warehouse.

It has a complete production line of colloidal gold and nucleic acid detection reagents, mainly engaged in the development of tuberculosis antibody colloidal gold detection kit and nucleic acid detection kit, HCG/LH two joint detection kit and 2019-nCoV detection kit. In response to the new crown epidemic, the company has successfully developed IgM, IgG and IgM/IgG detection cards, nucleic acid extraction and PCR kits, established the internal control panel of the enterprise, and met the daily verification requirements.

The product has started clinical trials in accordance with the relevant provisions of the NMPA. Before the end of June, the products have been evaluated, verified and used in more than ten countries and regions, and have been widely recognized by customers. The company's Novel coronavirus products have obtained domestic export qualification, CE certification, and have applied for Brazil ANVISA and US EUA certification